NUC,
Interesting that you bring up trust and Dr. Garnick's considerable track record.
For my money, the only thing I trust when it comes to this or any other company is it's track record, it's stock chart.
Until the chart says otherwise, I have to lump him in with the numerous other luminaries that are part of this company's past.
As far pharma paying up, who was it that was talking about how the end of phase II is an inflection point?
Hmmm, didn't we just complete a few of them?
If people here can be damned sure of manipulation going on even though they can't prove it then I sure as hell can state that any privileged knowledge of the data from those trials should have shown up in the stock chart by now.
But, all the chart is telling me is that there's no interest in this company. And, the absence of management buying shares, the lack of institutional ownership only adds to that opinion.
Everything I've seen or read so far points to the fact that the Bavi mAb will never be commercialized. At most, it could get an EUA and occupy some shelf space out of the DTRA, but it's never going any further than that.
IMHO, Garnick is here as a consultant to design the trials for the second generation Bavi mAb. More dilution to follow.
Regards,
moby
News 
Market Data 
Discover 
